Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Provention Bio (PRVB) Stock Price, News & Analysis

Provention Bio logo

About Provention Bio Stock (NASDAQ:PRVB)

Advanced Chart

Key Stats

Today's Range
$24.98
$24.98
50-Day Range
$23.74
$24.98
52-Week Range
$3.18
$25.00
Volume
218,200 shs
Average Volume
2.28 million shs
Market Capitalization
$2.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PRVB Stock News Headlines

Macrogenics Inc MGNX
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.tc pixel
Sanofi completes Provention Bio acquisition
See More Headlines

PRVB Stock Analysis - Frequently Asked Questions

Provention Bio, Inc. (NASDAQ:PRVB) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.08. The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $3.75 million. Provention Bio had a negative net margin of 880.69% and a negative trailing twelve-month return on equity of 103.36%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Provention Bio investors own include NVIDIA (NVDA), NIO (NIO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Meta Platforms (META), VBI Vaccines (VBIV) and Amarin (AMRN).

Company Calendar

Last Earnings
11/04/2021
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRVB
CIK
1695357
Fax
N/A
Employees
82
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$113.57 million
Net Margins
-880.69%
Pretax Margin
-984.54%
Return on Equity
-103.36%
Return on Assets
-69.08%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
1.93
Quick Ratio
1.92

Sales & Book Value

Annual Sales
$12.90 million
Price / Sales
183.54
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.40 per share
Price / Book
17.84

Miscellaneous

Outstanding Shares
94,780,000
Free Float
82,365,000
Market Cap
$2.37 billion
Optionable
Not Optionable
Beta
2.47

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:PRVB) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners